<code id='317027BD63'></code><style id='317027BD63'></style>
    • <acronym id='317027BD63'></acronym>
      <center id='317027BD63'><center id='317027BD63'><tfoot id='317027BD63'></tfoot></center><abbr id='317027BD63'><dir id='317027BD63'><tfoot id='317027BD63'></tfoot><noframes id='317027BD63'>

    • <optgroup id='317027BD63'><strike id='317027BD63'><sup id='317027BD63'></sup></strike><code id='317027BD63'></code></optgroup>
        1. <b id='317027BD63'><label id='317027BD63'><select id='317027BD63'><dt id='317027BD63'><span id='317027BD63'></span></dt></select></label></b><u id='317027BD63'></u>
          <i id='317027BD63'><strike id='317027BD63'><tt id='317027BD63'><pre id='317027BD63'></pre></tt></strike></i>

          
          WSS
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion